Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Intravitreal PP-001 in Chronic Non-Infectious Uveitis
NCT03634475Phase 2Completed
- Sponsor
- Panoptes Pharma
- Start
- Jan 2017
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of PaniDrop in noninfectious uveitis (NIU), sponsored by Panoptes Pharma. Primary endpoint: Treatment Emergent Adverse Events at 40 days. Started Jan 2017; status: completed.
02
Drugs
PaniDrop
03
Conditions
noninfectious uveitis (NIU)
Beyond the preview
Go deeper on NCT03634475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03634475.